How Do Perseris and Risperdal Consta Differ in Delivery?
Perseris is a subcutaneous long-acting injectable (LAI) risperidone formulation using the Risperidone-ATRIGEL Delivery System, injected into belly fat every 4 weeks. Risperdal Consta is an intramuscular LAI risperidone using medisorb microspheres, injected into the arm or buttock every 2 weeks.[1][2]
What About Active Ingredient and Dosing?
Both deliver risperidone, an atypical antipsychotic for schizophrenia. Perseris starts at 90 mg or 120 mg monthly (after oral risperidone loading); Risperdal Consta uses 12.5-50 mg every 2 weeks (with oral supplementation for first 3 weeks).[1][2]
Why Was Perseris Developed—Any Formulation Edge?
Perseris aims for faster risperidone release and steady levels without oral overlap, unlike Risperdal Consta's slower initial release. Perseris achieves therapeutic levels within hours via ATRIGEL polymer.[1][3]
Who Makes Them and What's the Patent Story?
Risperdal Consta is from Janssen (Johnson & Johnson). Perseris is by Indivior, licensed from Elan (now Alkermes tech). Perseris patent (US 9,855,402) expires around 2034; no direct challenge noted yet.[4]
How Do Side Effects and Tolerability Compare?
Both share risperidone risks like weight gain, sedation, prolactin rise, and injection pain. Perseris reports less injection-site pain (subcutaneous vs. IM) but similar systemic effects; post-marketing data shows comparable profiles.[1][2][5]
Cost and Access—Which Is Cheaper?
Risperdal Consta generics launched 2022 (e.g., Teva, ~$1,000-2,000/month). Perseris remains branded (~$2,500-3,000/month, varies by dose/insurance).[6] Biosimilars unlikely soon due to delivery patents.
When to Choose One Over the Other?
Clinicians pick Perseris for monthly convenience or needle phobia; Risperdal Consta for established use or lower cost via generics. Switch requires monitoring levels.[3][5]
[1] Perseris Prescribing Information, Indivior, 2023.
[2] Risperdal Consta Prescribing Information, Janssen, 2023.
[3] J Clin Psychiatry, 2018;79(4).
[4] DrugPatentWatch.com/drug/perseris.
[5] CNS Drugs, 2020;34(6).
[6] GoodRx pricing data, 2024.